longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Axsome Therap

AXSM

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Axsome presents Alzheimer’s agitation caregiver survey results at Psych Congress 2026

    PUBT·1 day ago, 11:01 AM
    AXSM-1.16%
  • 5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

    benzinga_article·1 day ago, 09:34 AM
    - U.S. stock indices finished the week mixed as investors evaluated varying performances across major market sectors. - Benzinga's Analyst Ratings API provides curated stock recommendations from top-performing Wall Street analysts to help investors navigate market uncertainties. - Recent updates feature rating adjustments and company developments from five highly accurate analysts regarding stocks such as ON Semiconductor, Axsome Therapeutics, Eli Lilly, StubHub Holdings, and Innodata.
    INOD+14.61%AXSM-1.16%
  • Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction

    Market Beat·Sep 19 at 06:02 PM
    AXSM-1.16%
  • Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

    Market Beat·Sep 19 at 08:02 AM
    AXSM-1.16%
  • Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

    Tip Ranks·Sep 18 at 11:26 AM
    AXSM-1.16%
  • Axsome Therapeutics (AXSM) Unveils New Depression And Alzheimer’s Agitation Data At Psych Congress 2026

    Simplywall·Sep 18 at 09:52 AM
    AXSM-1.16%
  • Is Axsome Therapeutics a Buy on the Dip?

    Motley Fool·Sep 18 at 07:46 AM
    AXSM-1.16%
  • AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials

    Quartr·Sep 9 at 09:30 PM
    AXSM-1.16%
  • Axsome COO Mark Jacobson sells 10,000 shares for $2.09 million

    PUBT·Sep 3 at 11:09 PM
    AXSM-1.16%
  • Axsome Therapeutics to present at H.C. Wainwright Global Investment Conference

    PUBT·Sep 2 at 11:02 AM
    AXSM-1.16%
  • Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

    Unusual Whales·Aug 31 at 11:02 AM
    AXSM-1.16%
  • Canada Pension Plan Investment Board Invests $55.17 Million in Axsome Therapeutics, Inc. $AXSM

    Market Beat·Aug 28 at 08:08 AM
    AXSM-1.16%
  • What is HC Wainwright's Estimate for AXSM Q4 Earnings?

    Market Beat·Aug 25 at 10:57 AM
    AXSM-1.16%GS-D-0.37%
  • Ram Selvaraju Reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution and AUVELITY Upside Potential

    Tip Ranks·Aug 24 at 10:25 AM
    AXSM-1.16%
  • Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

    Motley Fool·Aug 23 at 09:31 PM
    AXSM-1.16%